Prevalence and spectrum of BRCA germline variants in mainland Chinese familial breast and ovarian cancer patients
- PMID: 26848529
- PMCID: PMC4891063
- DOI: 10.18632/oncotarget.7144
Prevalence and spectrum of BRCA germline variants in mainland Chinese familial breast and ovarian cancer patients
Abstract
Germline mutations in BRCA1 and BRCA2 are the most penetrating genetic predispositions for breast and ovarian cancer, and their presence is largely ethnic-specific. Comprehensive information about the prevalence and spectrum of BRCA mutations has been collected in European and North American populations. However, similar information is lacking in other populations, including the mainland Chinese population despite its large size of 1.4 billion accounting for one fifth of the world's population. Herein, we performed an extensive literature analysis to collect BRCA variants identified from mainland Chinese familial breast and ovarian cancer patients. We observed 137 distinct BRCA1 variants in 409 of 3,844 and 80 distinct BRCA2 variants in 157 of 3,024 mainland Chinese patients, with an estimated prevalence of 10.6% for BRCA1 and 5.2% for BRCA2. Of these variants, only 40.3% in BRCA1 and 42.5% in BRCA2 are listed in current Breast Cancer Information Core database. We observed higher frequent variation in BRCA1 exons 11A, 11C, 11D, and 24 and BRCA2 exon 10 in Chinese patients than in the patients of other populations. The most common pathogenic variant in BRCA1 wasc.981_982delAT in exon 11A, and in BRCA2 c.3195_3198delTAAT in exon 11B and c.5576_5579delTTAA in exon 11E; the most common novel variant in BRCA1 was c.919A>G in exon 10A, and in BRCA2 c.7142delC in exon 14. None of the variants overlap with the founder mutations in other populations. Our analysis indicates that the prevalence of BRCA variation in mainland Chinese familial breast and ovarian cancer patients is at a level similar to but the spectrum is substantially different from the ones of other populations.
Keywords: BRCA1; BRCA2; familial breast and ovarian cancer; germline variant; mainland Chinese.
Conflict of interest statement
The authors declare no competing interests.
Figures




Similar articles
-
BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls.Gynecol Oncol. 2018 Oct;151(1):145-152. doi: 10.1016/j.ygyno.2018.07.024. Epub 2018 Aug 2. Gynecol Oncol. 2018. PMID: 30078507
-
Novel germline mutations and unclassified variants of BRCA1 and BRCA2 genes in Chinese women with familial breast/ovarian cancer.BMC Cancer. 2016 Feb 6;16:64. doi: 10.1186/s12885-016-2107-6. BMC Cancer. 2016. PMID: 26852015 Free PMC article.
-
Germline variation in BRCA1/2 is highly ethnic-specific: Evidence from over 30,000 Chinese hereditary breast and ovarian cancer patients.Int J Cancer. 2019 Aug 15;145(4):962-973. doi: 10.1002/ijc.32176. Epub 2019 Feb 13. Int J Cancer. 2019. PMID: 30702160 Free PMC article.
-
Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa.BMC Cancer. 2022 Feb 25;22(1):208. doi: 10.1186/s12885-022-09181-4. BMC Cancer. 2022. PMID: 35216584 Free PMC article.
-
Pathogenic variants in BRCA1 and BRCA2 genes associated with female breast and ovarian cancer in the Mexican population.J Med Life. 2025 Jan;18(1):38-47. doi: 10.25122/jml-2024-0213. J Med Life. 2025. PMID: 40071159 Free PMC article.
Cited by
-
Core promoter in TNBC is highly mutated with rich ethnic signature.Brief Funct Genomics. 2023 Jan 20;22(1):9-19. doi: 10.1093/bfgp/elac035. Brief Funct Genomics. 2023. PMID: 36307127 Free PMC article.
-
Pathogenic variant burden in the ExAC database: an empirical approach to evaluating population data for clinical variant interpretation.Genome Med. 2017 Feb 6;9(1):13. doi: 10.1186/s13073-017-0403-7. Genome Med. 2017. PMID: 28166811 Free PMC article.
-
High Frequency of BRCA2 c.5576_5579del Carriers in Kakogawa, Japan.Cancer Diagn Progn. 2024 May 3;4(3):309-314. doi: 10.21873/cdp.10325. eCollection 2024 May-Jun. Cancer Diagn Progn. 2024. PMID: 38707742 Free PMC article.
-
Germline variants analysis of Chinese breast cancer patients reveals numerous alterations in homologous recombination genes.Future Sci OA. 2025 Dec;11(1):2458432. doi: 10.1080/20565623.2025.2458432. Epub 2025 Apr 1. Future Sci OA. 2025. PMID: 40167152 Free PMC article.
-
Allele-specific expression mediates primary resistance to poly (ADP-ribose) polymerase inhibitor therapy in a case of BRCA1/2 double-germline mutant gastric cancer.J Int Med Res. 2020 Mar;48(3):300060519886226. doi: 10.1177/0300060519886226. Epub 2019 Nov 27. J Int Med Res. 2020. PMID: 31774011 Free PMC article.
References
-
- Pavlicek A, Noskov VN, Kouprina N, Barrett JC, Jurka J, Larionov V. Evolution of the tumor suppressor BRCA1 locus in primates: implications for cancer predisposition. Hum Mol Genet. 2004;13:2737–2751. - PubMed
-
- Jin H, Selfe J, Whitehouse C, Morris JR, Solomon E, Roberts RG. Structural evolution of the BRCA1 genomic region in primates. Genomics. 2004;84:1071–1082. - PubMed
-
- Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC. Linkage of early-onset familial breast cancer to chromosome 17q21. Science. 1990;250:1684–1689. - PubMed
-
- Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66–71. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous